Nine years after Sarepta Therapeutics’ Exondys 51 won a controversial FDA approval to treat a subset of patients with Duchenne muscular dystrophy (DMD), a challenger from Massachusetts biotech Dyne ...
What if you could flip a genetic switch to silence a gene, then turn it back on with a simple drug? For researchers, gene-switch tools offer that kind of control—and a new system called Cyclone may ...
Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...
i have an issue with a very crowded sashimi plot of a whole gene that is difficult to read: this gets even worse if a add a white background to text. i know i could just zoom into the event, but i ...
BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as ...
This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...
In a primary efficacy population of 85 patients, the confirmed overall response rate was 46%. The Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy ® (sunvozertinib) for ...
Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...
Hello, I'm wondering if there's a setting or if other people have this issue as well (searching I could not find it). When we map with STAR, most of our data looks great. However, a small number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback